Search

Your search keyword '"MOK, Tony"' showing total 601 results
Start Over Author "MOK, Tony" Search Limiters Peer Reviewed
601 results on '"MOK, Tony"'

1. Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer

Author

Saw, Stephanie P.L., Zhong, Wen-Zhao, Fu, Rui, Li, Molly S.C., Goto, Yasushi, Fox, Stephen B., Yatabe, Yasushi, Ong, Boon-Hean, Ng, Calvin S.H., Lee, David D.W., Cam Phuong, Pham, Park, In Kyu, Yang, James C.H., Tsuboi, Masahiro, Tho, Lye Mun, John, Thomas, Hsu, Hsao-Hsun, Tan, Daniel S.W., Mok, Tony S.K., Reungwetwattana, Thanyanan, and Singh, Navneet

Published
2025
Full Text
View/download PDF

4. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial

Author

Peters, Solange, Cho, Byoung Chul, Luft, Alexander V., Alatorre-Alexander, Jorge, Geater, Sarayut Lucien, Laktionov, Konstantin, Trukhin, Dmytro, Kim, Sang-We, Ursol, Grygorii M., Hussein, Maen, Lim, Farah Louise, Yang, Cheng-Ta, Araujo, Luiz Henrique, Saito, Haruhiro, Reinmuth, Niels, Lowery, Caitlin, Mann, Helen, Stewart, Ross, Jiang, Haiyi, Garon, Edward B., Mok, Tony, and Johnson, Melissa L.

Published
2025
Full Text
View/download PDF

6. Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC

Author

Saw, Stephanie P.L., Low, Yi Fen, Lai, Gillianne G.Y., Chan, Landon L., Wong, Wesley K.Y., Tsui, Giselle, Chen, Olivia H., Seet, Amanda O.L., Tan, Wei Chong, Tan, Aaron C., Chan, Johan W.K., Teh, Yi Lin, Tan, Wan-Ling, Ng, Quan Sing, Ang, Mei-Kim, Kanesvaran, Ravindran, Lim, Darren W.T., Tan, Daniel S.W., Mok, Tony S.K., and Li, Molly S.C.

Published
2024
Full Text
View/download PDF

10. Allelic Context of EGFR C797X–Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes

Author

Lu, Chang, Wei, Xue-Wu, Wang, Zhen, Zhou, Zhen, Liu, Yu-Tao, Zheng, Di, He, Yong, Xie, Zhan-Hong, Li, Yong, Zhang, Yan, Zhang, Yi-Chen, Huang, Zi-Jian, Mei, Shi-Qi, Liu, Jia-Qi, Guan, Xu-Hui, Deng, Yu, Chen, Zhi-Hong, Tu, Hai-Yan, Xu, Chong-Rui, Chen, Hua-Jun, Zhong, Wen-Zhao, Yang, Jin-Ji, Zhang, Xu-Chao, Mok, Tony S.K., Wu, Yi-Long, and Zhou, Qing

Published
2024
Full Text
View/download PDF

16. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)

Author

Garon, Edward B., Cho, Byoung Chul, Luft, Alexander, Alatorre-Alexander, Jorge, Geater, Sarayut Lucien, Kim, Sang-We, Ursol, Grygorii, Hussein, Maen, Lim, Farah Louise, Yang, Cheng-Ta, Araujo, Luiz Henrique, Saito, Haruhiro, Reinmuth, Niels, Medic, Nenad, Mann, Helen, Shi, Xiaojin, Peters, Solange, Mok, Tony, and Johnson, Melissa

Published
2023
Full Text
View/download PDF

17. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide

Author

Liu, Stephen V., Mok, Tony S.K., Nabet, Barzin Y., Mansfield, Aaron S., De Boer, Richard, Losonczy, György, Sugawara, Shunichi, Dziadziuszko, Rafal, Krzakowski, Maciej, Smolin, Alexey, Hochmair, Maximilian J., Garassino, Marina C., Gay, Carl M., Heymach, John V., Byers, Lauren A., Lam, Sivuonthanh, Cardona, Andrés, Morris, Stefanie, Adler, Leah, Shames, David S., and Reck, Martin

Published
2023
Full Text
View/download PDF

18. Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

Author

Zhou, Qing, Soo, Ross A., Chang, Gee-Chen, Chiu, Chao-Hua, Hayashi, Hidetoshi, Kim, Sang-We, Teraoka, Shunsuke, Goto, Yasushi, Zhou, Jianying, Ho-Fun Lee, Victor, Kim, Dong-Wan, Han, Baohui, Chung Man Ho, James, Lin, Chia-Chi, Lu, Shun, Polli, Anna, Calella, Anna Maria, Martini, Jean-François, Wong, Chew Hooi, Mok, Tony, Kim, Hye Ryun, and Wu, Yi-Long

Published
2023
Full Text
View/download PDF

20. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Author

Peters, Solange, Dziadziuszko, Rafal, Morabito, Alessandro, Felip, Enriqueta, Gadgeel, Shirish M., Cheema, Parneet, Cobo, Manuel, Andric, Zoran, Barrios, Carlos H., Yamaguchi, Masafumi, Dansin, Eric, Danchaivijitr, Pongwut, Johnson, Melissa, Novello, Silvia, Mathisen, Michael S., Shagan, Sarah M., Schleifman, Erica, Wang, Jin, Yan, Mark, Mocci, Simonetta, Voong, David, Fabrizio, David A., Shames, David S., Riehl, Todd, Gandara, David R., and Mok, Tony

Published
2022
Full Text
View/download PDF

21. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations

Author

Ahn, Myung-Ju, Mendoza, Marvin Jonne L., Pavlakis, Nick, Kato, Terufumi, Soo, Ross A., Kim, Dong-Wan, Liam, Chong Kin, Hsia, Te-Chun, Lee, Chee Khoon, Reungwetwattana, Thanyanan, Geater, Sarayut, Chan, Oscar Siu Hong, Prasongsook, Naiyarat, Solomon, Benjamin J., Nguyen, Thi Thai Hoa, Kozuki, Toshiyuki, Yang, James Chih-Hsin, Wu, Yi-Long, Mok, Tony Shu Kam, Tan, Daniel Shao-Weng, and Yatabe, Yasushi

Published
2022
Full Text
View/download PDF

25. Artificial intelligence–powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response

Author

Choi, Sangjoon, Cho, Soo Ick, Ma, Minuk, Park, Seonwook, Pereira, Sergio, Aum, Brian Jaehong, Shin, Seunghwan, Paeng, Kyunghyun, Yoo, Donggeun, Jung, Wonkyung, Ock, Chan-Young, Lee, Se-Hoon, Choi, Yoon-La, Chung, Jin-Haeng, Mok, Tony S., Kim, Hyojin, and Kim, Seokhwi

Published
2022
Full Text
View/download PDF

26. Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.

Author

Solomon, Benjamin J, Liu, Geoffrey, Felip, Enriqueta, K Mok, Tony S, Soo, Ross A, Mazieres, Julien, Shaw, Alice T, Marinis, Filippo de, Goto, Yasushi, Wu, Yi-Long, Kim, Dong-Wan, Martini, Jean-François, Messina, Rossella, Paolini, Jolanda, Polli, Anna, Thomaidou, Despina, Toffalorio, Francesca, and Bauer, Todd M

Abstract

What is this study about? This is a summary of the results of an ongoing study called CROWN. In the CROWN study, researchers looked at the effects of two medicines called lorlatinib (Lorbrena) and crizotinib (Xalkori) for people with advanced non-small cell lung cancer (NSCLC) who had not been treated yet. Everyone in the study had changes in a gene called anaplastic lymphoma kinase, or ALK, in their cancer cells. The changes in the ALK gene can make cancer grow. This analysis looked at how well lorlatinib and crizotinib worked and their side effects in people with advanced ALK-positive NSCLC after 5 years. What did this study find? After observing people for an average of 5 years, researchers found that more people who took lorlatinib were still alive without their cancer getting worse than the people who took crizotinib. At 5 years, the probability of being alive without their cancer getting worse was 60% in people who took lorlatinib compared with 8% in people who took crizotinib. Fewer people who took lorlatinib had their cancer spread within or to the brain than the people who took crizotinib. In more than half of the people who took lorlatinib, tumors that had spread to the brain did not get worse, and no new tumors spread to the brain after 5 years. In contrast, in about half of the people who took crizotinib, tumors that had spread to the brain got worse or new tumors spread to the brain after 16.4 months. More people who took lorlatinib (115 out of 149, or 77%) had severe or life-threatening side effects than people who took crizotinib (81 out of 142, or 57%). These side effects were like the ones reported in the earlier 3-year analysis. What do the findings of the study mean? The 5-year results from the CROWN study showed that more people who took lorlatinib continued to benefit from their treatment than those who took crizotinib. The 5-year benefit of lorlatinib in people with ALK-positive NSCLC has never been seen before. Clinical Trial Registration:NCT03052608 (Phase 3 CROWN study) (ClinicalTrials.gov) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Next-generation immunotherapy: igniting new hope for lung cancer.

Author

Li, Molly S. C., Chan, Andrew L. S., Mok, Kevin K. S., Chan, Landon L., and Mok, Tony S. K.

Abstract

Adoption of immunotherapy has completely transformed the treatment landscape of cancer. Patients with advanced cancer treated with immunotherapy may benefit from durable tumor response and long-term survival. The most widely used immunotherapy in solid tumors is anti-programmed-death (ligand) protein (PD-(L)1), which is now an integral part of non-small cell lung cancer (NSCLC) treatment irrespective of histological cell types and tumor stage. However, the vast majority of patients with advanced NSCLC treated with anti-PD-(L)1 still develop therapeutic resistance, and the prognosis after anti-PD-(L)1 resistance is poor. Resistance mechanisms to PD-1 blockade are often complex and encompass a combination of defects within the cancer-immunity cycle. These defects include failure in antigen presentation and T-cell priming, presence of co-inhibitory immune checkpoints, inability of immune cells to infiltrate the tumor, and presence of immunosuppressive tumor microenvironment. Recently, advances in drug design, genomic sequencing, and gene editing technologies have led to development of next-generation immunotherapies that may potentially overcome these resistance mechanisms. In this review, we will discuss the anti-PD-(L)1 resistance mechanism landscape in NSCLC and four novel modalities of immunotherapy in detail, namely novel immune checkpoint inhibitor and targeted therapy combinations, bispecific antibodies, cancer vaccine, and cell therapy. These novel therapeutics have all demonstrated early clinical data in NSCLC treatment and may work synergistically with each other to restore anticancer immunity. In addition, we share our perspectives on the future promises and challenges in the transformation of these novel immunotherapies to standard clinical care. Plain language summary: Next generation immunotherapy in lung cancer Immune checkpoint inhibitor with anti-programme-death (ligand) protein (PD-[L]1) is the standard of care for lung cancer treatment however therapeutic resistance is common. Various mechanisms are implicated in immune checkpoint inhibitor resistance. Recently, new generations of immunotherapies including novel immune checkpoint inhibitors, bispecific antibodies, cancer vaccine and cell therapy, have been developed. These novel therapeutics have demonstrated early promising data in lung cancer treatment. In this review, we will discuss these novel immunotherapies in detail and share our perspectives on the future promises and challenges in moving them to standard clinical care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.

Author

Pu, Xingxiang, Li, Juan, Zhang, Bo, Zhang, Jinyao, K Mok, Tony S, Nakagawa, Kazuhiko, Rosell, Rafael, Cheng, Ying, Zhou, Xiangdong, Miglorino, Maria Rita, Niho, Seiji, Lee, Ki Hyeong, Corral, Jesus, Pluzanski, Adam, Li, Junling, Linke, Rolf, Pan, Fang, Tang, Yiyun, Tan, Weiwei, and Wu, Lin

Abstract

Aim: We investigated association between skin adverse events (AEs) and efficacy with dacomitinib in patients with EGFR-positive non-small-cell lung cancer (NSCLC). Methods:Post hoc analyses from ARCHER 1050 evaluated efficacy in patients who did and did not experience grade ≥2 skin AEs with dacomitinib. Landmark analyses were performed at 3 and 6 months. Results: In patients who had skin AEs (72.2%) vs. those who did not (27.7%), median progression-free survival was 16.0 vs. 9.2 months, median overall survival (OS) was 37.7 vs. 21.6 months, and objective response rate was 80.2 vs. 61.5%; OS was improved at 3 and 6 months landmark analyses. Conclusion: Presence of grade ≥2 skin AEs was associated with numerically improved efficacy and represents a valuable biomarker of treatment outcome with dacomitinib in patients with advanced NSCLC. Clinical Trial Registration:NCT01774721 (ClinicalTrials.gov) Plain Language Summary The ARCHER 1050 study assessed how the drugs called dacomitinib and gefitinib affected people with non-small-cell lung cancer (NSCLC) who had mutations in the EGFR gene. In this study, people who were treated with dacomitinib lived longer without their cancer getting worse than people who were treated with gefitinib. Skin adverse reactions were higher in people who were treated with dacomitinib than gefitinib. In this follow-up analysis, researchers wanted to see if the treatment effect of dacomitinib was different between people who had skin adverse reactions and people who did not have skin adverse reactions after treatment with dacomitinib. The results from this analysis showed that after treatment with dacomitinib, half of the people who had skin adverse reactions lived for 16.0 months, and half of the people who did not have skin adverse reactions lived for 9.2 months without their cancer getting worse. This study also showed that half of the people who had skin adverse reactions lived for 37.7 months, and half of the people who did not have skin adverse reactions lived for 21.6 months. In summary, the results from this study showed that the treatment effect of dacomitinib was better in people who had skin adverse reactions after treatment with dacomitinib. Therefore, skin adverse reactions can be a marker of better treatment effect in people with NSCLC who had mutations in the EGFR gene when treated with dacomitinib. Article highlights. Introduction In the Phase III ARCHER 1050 study, dacomitinib showed improved progression-free survival vs. gefitinib in patients with EGFR-positive non-small-cell lung cancer (NSCLC). Methods The association between the presence of skin-related adverse events (AEs) and improved efficacy of EGFR tyrosine kinase inhibitors was assessed. Results The presence of grade ≥2 skin AEs was associated with numerically improved efficacy in patients treated with dacomitinib. Conclusions Skin AEs may represent a clinically valuable biomarker of treatment outcome in patients with advanced NSCLC treated with dacomitinib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Calls to action on lung cancer management and research.

Author

Meyer, May-Lucie, Hirsch, Fred R, Bunn, Paul A, Ujhazy, Peter, Fredrickson, David, Berg, Christine D, Carbone, David P, Halmos, Balazs, Singh, Harpreet, Borghaei, Hossein, Ferris, Andrea, Langer, Corey, Dacic, Sanja, Mok, Tony S, Peters, Solange, and Johnson, Bruce E

Subjects
TREATMENT of lung tumors, SMOKING cessation, INTERPROFESSIONAL relations, DISEASE management, CLINICAL medicine research, EARLY detection of cancer, IMMUNOTHERAPY, TUMOR markers, PUBLIC health
Abstract

Lung cancer, the leading cause of cancer-related deaths globally, remains a pressing health issue despite significant medical advances. The New York Lung Cancer Foundation brought together experts from academia, the pharmaceutical and biotech industries as well as organizational leaders and patient advocates, to thoroughly examine the current state of lung cancer diagnosis, treatment, and research. The goal was to identify areas where our understanding is incomplete and to develop collaborative public health and scientific strategies to generate better patient outcomes, as highlighted in our "Calls to Action." The consortium prioritized 8 different calls to action. These include (1) develop strategies to cure more patients with early-stage lung cancer, (2) investigate carcinogenesis leading to lung cancers in patients without a history of smoking, (3) harness precision medicine for disease interception and prevention, (4) implement solutions to deliver prevention measures and effective therapies to individuals in under-resourced countries, (5) facilitate collaborations with industry to collect and share data and samples, (6) create and maintain open access to big data repositories, (7) develop new immunotherapeutic agents for lung cancer treatment and prevention, and (8) invest in research in both the academic and community settings. These calls to action provide guidance to representatives from academia, the pharmaceutical and biotech industries, organizational and regulatory leaders, and patient advocates to guide ongoing and planned initiatives. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer

Author

Chang, Jianhua, Wu, Yi-Long, Lu, Shun, Wang, Jie, Mok, Tony, Zhang, Li, Feng, Jifeng, Wu, Lin, Tu, Hai-Yan, Zhang, Yiping, Luft, Alexander, Zhou, Jian-ying, Ma, Zhiyong, Lu, You, Hu, Chengping, Shi, Yuankai, Poddubskaya, Elena, Soo, Ross A., Chia, Yee Hong, Penrod, John R., Taylor, Fiona, Lawrance, Rachael, Blum, Steven I., Sun, Xiaowu, Juarez-Garcia, Ariadna, Moreno-Koehler, Alejandro, Li, Ang, Li, Amy, and Cheng, Ying

Published
2022
Full Text
View/download PDF

31. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Author

Nogami, Naoyuki, Barlesi, Fabrice, Socinski, Mark A., Reck, Martin, Thomas, Christian A., Cappuzzo, Federico, Mok, Tony S.K., Finley, Gene, Aerts, Joachim G., Orlandi, Francisco, Moro-Sibilot, Denis, Jotte, Robert M., Stroyakovskiy, Daniil, Villaruz, Liza C., Rodríguez-Abreu, Delvys, Wan-Teck Lim, Darren, Merritt, David, Coleman, Shelley, Lee, Anthony, Shankar, Geetha, Yu, Wei, Bara, Ilze, and Nishio, Makoto

Published
2022
Full Text
View/download PDF

32. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Author

Adamchuk, Grigory, Ahn, Myung-Ju, Alexandru, Aurelia, Altundag, Ozden, Alyasova, Anna, Andrusenko, Orest, Aoe, Keisuke, Araujo, Antonio, Aren, Osvaldo, Arrieta Rodriguez, Oscar, Ativitavas, Touch, Avendano, Oscar, Barata, Fernando, Barrios, Carlos Henrique, Beato, Carlos, Bergstrom, Per, Betticher, Daniel, Bolotina, Larisa, Bondarenko, Igor, Botha, Michiel, Buddu, Sayeuri, Caglevic, Christian, Cardona, Andres, Castro, Gilberto, Jr, Castro, Hugo, Cay Senler, Filiz, Cerny, Carlos Alexandre Sydow, Cesas, Alvydas, Chan, Gee-Chen, Chang, Jianhua, Chen, Gongyan, Chen, Xi, Cheng, Susanna, Cheng, Ying, Cherciu, Nelly, Chiu, Chao-Hua, Cho, Byoung Chul, Cicenas, Saulius, Ciurescu, Daniel, Cohen, Graham, Costa, Marcos Andre, Danchaivijitr, Pongwut, De Angelis, Flavia, de Azevedo, Sergio Jobim, Dediu, Mircea, Deliverski, Tsvetan, De Marchi, Pedro Rafael Martins, de The Bustamante Valles, Flor, Ding, Zhenyu, Doganov, Boyan, Dreosti, Lydia, Duarte, Ricardo, Edusma-Dy, Regina, Emelyanov, Sergey, Erman, Mustafa, Fan, Yun, Fein, Luis, Feng, Jifeng, Fenton, David, Fernandes, Gustavo, Ferreira, Carlos, Franke, Fabio Andre, Freitas, Helano, Fujisaka, Yasuhito, Galindo, Hector, Galvez, Christina, Ganea, Doina, Gil, Nuno, Girotto, Gustavo, Goker, Erdem, Goksel, Tuncay, Gomez Aubin, Gonzalo, Gomez Wolff, Luis, Griph, Hakan, Gumus, Mahmut, Hall, Jacqueline, Hart, Gregory, Havel, Libor, He, Jianxing, He, Yong, Hernandez Hernandez, Carlos, Hespanhol, Venceslau, Hirashima, Tomonori, Ho, Chung Man James, Horiike, Atsushi, Hosomi, Yukio, Hotta, Katsuyuki, Hou, Mei, How, Soon Hin, Hsia, Te-Chun, Hu, Yi, Ichiki, Masao, Imamura, Fumio, Ivashchuk, Oleksandr, Iwamoto, Yasuo, Jaal, Jana, Jassem, Jacek, Jordaan, Christa, Juergens, Rosalyn Anne, Kaen, Diego, Kalinka-Warzocha, Ewa, Karaseva, Nina, Karaszewska, Boguslawa, Kazarnowicz, Andrzej, Kasahara, Kazuo, Katakami, Nobuyuki, Kato, Terufumi, Kawaguchi, Tomoya, Kim, Joo Hang, Kishi, Kazuma, Kolek, Vitezslav, Koleva, Marchela, Kolman, Petr, Koubkova, Leona, Kowalyszyn, Ruben, Kowalski, Dariusz, Koynov, Krassimir, Ksienski, Doran, Kubota, Kaoru, Kudaba, Iveta, Kurata, Takayasu, Kuusk, Gerli, Kuzina, Lyudmila, Laczo, Ibolya, Ladrera, Guia Elena Imelda, Laktionov, Konstantin, Landers, Gregory, Lazarev, Sergey, Lerzo, Guillermo, Lesniewski Kmak, Krzysztof, Li, Wei, Liam, Chong Kin, Lifirenko, Igor, Lipatov, Oleg, Liu, Xiaoqing, Liu, Zhe, Lo, Sing Hung, Lopes, Valeria, Lopez, Karla, Lu, Shun, Martinengo, Gaston, Mas, Luis, Matrosova, Marina, Micheva, Rumyana, Milanova, Zhasmina, Miron, Lucian, Mok, Tony, Molina, Matias, Murakami, Shuji, Nakahara, Yasuharu, Nguyen, Tien Quang, Nishimura, Takashi, Ochsenbein, Adrian, Ohira, Tatsuo, Ohman, Ronny, Ong, Choo Khoon, Ostoros, Gyula, Ouyang, Xuenong, Ovchinnikova, Elena, Ozyilkan, Ozgur, Petruzelka, Lubos, Pham, Xuan Dung, Picon, Pablo, Piko, Bela, Poltoratsky, Artem, Ponomarova, Olga, Popelkova, Patrice, Purkalne, Gunta, Qin, Shukui, Ramlau, Rodryg, Rappaport, Bernardo, Rey, Felipe, Richardet, Eduardo, Roubec, Jaromir, Ruff, Paul, Rusyn, Andrii, Saka, Hideo, Salas, Jorge, Sandoval, Mario, Santos, Lucas, Sawa, Toshiyuki, Seetalarom, Kasan, Seker, Mesut, Seki, Nobuhiko, Seolwane, Freddy, Shepherd, Lucinda, Shevnya, Sergii, Shimada, Andrea Kazumi, Shparyk, Yaroslav, Sinielnikov, Ivan, Sirbu, Daniela, Smaletz, Oren, Soares, Joao Paulo Holanda, Sookprasert, Aumkhae, Speranza, Giovanna, Srimuninnimit, Vichien, Sriuranpong, Virote, Stara, Zinaida, Su, Wu-Chou, Sugawara, Shunichi, Szpak, Waldemar, Takahashi, Kazuhisa, Takigawa, Nagio, Tanaka, Hiroshi, Tan Chun Bing, Jerry, Tang, Qiyou, Taranov, Pavel, Tejada, Hermes, Tho, Lye Mun, Torii, Yoshitaro, Trukhyn, Dmytro, Turdean, Maria, Turna, Hande, Ursol, Grygoriy, Vanasek, Jaroslav, Varela, Mirta, Vallejo, Marcela, Vera, Luis, Victorino, Ana-Paula, Vlasek, Tomas, Vynnychenko, Ihor, Wang, Buhai, Wang, Jie, Wang, Kai, Wu, Yilong, Yamada, Kazuhiko, Yang, Chih-Hsin, Yokoyama, Takuma, Yokoyama, Toshihide, Yoshioka, Hiroshige, Yumuk, Fulden, Zambrano, Angela, Zarba, Juan Jose, Zarubenkov, Oleg, Zemaitis, Marius, Zhang, Li, Zhang, Xin, Zhao, Jun, Zhou, Caicun, Zhou, Jianying, Zhou, Qing, Zippelius, Alfred, Mok, Tony S K, Wu, Yi-Long, Kowalski, Dariusz M, Turna, Hande Z, Laktionov, Konstantin K, Lubiniecki, Gregory M, Zhang, Jin, Kush, Debra, and Lopes, Gilberto

Published
2019
Full Text
View/download PDF

33. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Author

Reck, Martin, Mok, Tony SK, Nishio, Makoto, Jotte, Robert M, Cappuzzo, Federico, Orlandi, Francisco, Stroyakovskiy, Daniil, Nogami, Naoyuki, Rodríguez-Abreu, Delvys, Moro-Sibilot, Denis, Thomas, Christian A, Barlesi, Fabrice, Finley, Gene, Lee, Anthony, Coleman, Shelley, Deng, Yu, Kowanetz, Marcin, Shankar, Geetha, Lin, Wei, Socinski, Mark A, and Mok, Tony S K

Published
2019
Full Text
View/download PDF

34. Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

Author

Dziadziuszko, Rafal, Mok, Tony, Peters, Solange, Han, Ji-Youn, Alatorre-Alexander, Jorge, Leighl, Natasha, Sriuranpong, Virote, Pérol, Maurice, de Castro Junior, Gilberto, Nadal, Ernest, de Marinis, Filippo, Frontera, Osvaldo Arén, Tan, Daniel S.W., Lee, Dae Ho, Kim, Hye Ryun, Yan, Mark, Riehl, Todd, Schleifman, Erica, Paul, Sarah M., Mocci, Simonetta, Patel, Rajesh, Assaf, Zoe June, Shames, David S., Mathisen, Michael S., and Gadgeel, Shirish M.

Published
2021
Full Text
View/download PDF

35. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Author

Rolfo, Christian, Mack, Philip, Scagliotti, Giorgio V., Aggarwal, Charu, Arcila, Maria E., Barlesi, Fabrice, Bivona, Trever, Diehn, Maximilian, Dive, Caroline, Dziadziuszko, Rafal, Leighl, Natasha, Malapelle, Umberto, Mok, Tony, Peled, Nir, Raez, Luis E., Sequist, Lecia, Sholl, Lynette, Swanton, Charles, Abbosh, Chris, Tan, Daniel, Wakelee, Heather, Wistuba, Ignacio, Bunn, Rebecca, Freeman-Daily, Janet, Wynes, Murry, Belani, Chandra, Mitsudomi, Tetsuya, and Gandara, David

Published
2021
Full Text
View/download PDF

36. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

Author

Mansfield, Aaron S., Herbst, Roy S., de Castro, Gilberto, Jr., Hui, Rina, Peled, Nir, Kim, Dong-Wan, Novello, Silvia, Satouchi, Miyako, Wu, Yi-Long, Garon, Edward B., Reck, Martin, Robinson, Andrew G., Samkari, Ayman, Piperdi, Bilal, Ebiana, Victoria, Lin, Jianxin, and Mok, Tony S.K.

Published
2021
Full Text
View/download PDF

38. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

Author

Lau, George, Yu, Ming-Lung, Wong, Grace, Thompson, Alexander, Ghazinian, Hasmik, Hou, Jin-Lin, Piratvisuth, Teerha, Jia, Ji-Dong, Mizokami, Masashi, Cheng, Gregory, Chen, Guo-Feng, Liu, Zhen-Wen, Baatarkhuu, Oidov, Cheng, Ann Lii, Ng, Woon Leung, Lau, Patrick, Mok, Tony, Chang, Jer-Ming, Hamid, Saeed, Dokmeci, A. Kadir, Gani, Rino A., Payawal, Diana A., Chow, Pierce, Park, Joong-Won, Strasser, Simone I., Mohamed, Rosmawaiti, Win, Khin Maung, Tawesak, Tanwandee, Sarin, Shiv Kumar, and Omata, Masao

Published
2021
Full Text
View/download PDF

40. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)

Author

Cheng, Ying, Mok, Tony S., Zhou, Xiangdong, Lu, Shun, Zhou, Qing, Zhou, Jianying, Du, Yingying, Yu, Ping, Liu, Xiaoqing, Hu, Chengping, Lu, You, Zhang, Yiping, Lee, Ki Hyeong, Nakagawa, Kazuhiko, Linke, Rolf, Wong, Chew Hooi, Tang, Yiyun, Zhu, Fanfan, Wilner, Keith D., and Wu, Yi-Long

Published
2021
Full Text
View/download PDF

43. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Author

Lu, Shun, Wang, Jie, Cheng, Ying, Mok, Tony, Chang, Jianhua, Zhang, Li, Feng, Jifeng, Tu, Hai-Yan, Wu, Lin, Zhang, Yiping, Luft, Alexander, Zhou, Jian-ying, Ma, Zhiyong, Lu, You, Hu, Chengping, Shi, Yuankai, Ying, Kejing, Zhong, Hua, Poddubskaya, Elena, Soo, Ross A, Chia, Yee Hong, Li, Ang, Li, Amy, and Wu, Yi-Long

Published
2021
Full Text
View/download PDF

44. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.

Author

Solomon, Benjamin J., Liu, Geoffrey, Felip, Enriqueta, Mok, Tony S.K., Soo, Ross A., Mazieres, Julien, Shaw, Alice T., de Marinis, Filippo, Goto, Yasushi, Wu, Yi-Long, Kim, Dong-Wan, Martini, Jean-François, Messina, Rossella, Paolini, Jolanda, Polli, Anna, Thomaidou, Despina, Toffalorio, Francesca, and Bauer, Todd M.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results